Literature DB >> 21761358

Risk of mortality by histologic type of breast cancer in the United States.

Christopher I Li1.   

Abstract

There are several histologic types of breast cancer that beyond their histopathologic differences have distinct clinical characteristics. However, it is unclear how histology is related to risk of mortality particularly when differences in hormone receptor status, tumor size, and nodal status are incorporated. This study utilized a cohort of 319,463 breast cancer patients ≥30 years of age diagnosed from 1992 to 2007 identified from 17 population-based cancer registries that participate in the Surveillance Epidemiology and End Results Program. Multivariate adjusted risks of mortality associated with seven breast cancer histologic subtypes were estimated using Cox regression. Mucinous, tubular, and medullary carcinomas were associated with 31-79% lower risks of mortality compared to ductal carcinoma. Inflammatory breast cancer was associated with a 50-53% increased risk of mortality depending on age. While lobular carcinomas carried the same risk of mortality as ductal carcinoma among women 30-49 years of age, among women ≥50 years of age with node-negative disease lobular carcinoma was associated with an 11% reduced risk of mortality, but among those with node-positive disease it was associated with a 10% increased risk of mortality. This study confirms that mucinous, tubular, and medullary carcinomas have a more favorable prognosis compared to ductal carcinoma, and that inflammatory carcinoma has a poorer prognosis. Though many of these histologic subtypes are quite rare, consideration of the mortality risk associated with a given subtype may be clinically useful when making decisions regarding treatment and follow-up.

Entities:  

Mesh:

Year:  2010        PMID: 21761358     DOI: 10.1007/s12672-010-0016-8

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  14 in total

1.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Authors:  Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine
Journal:  J Natl Cancer Inst       Date:  2005-07-06       Impact factor: 13.506

2.  Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands.

Authors:  Marieke W J Louwman; Martine Vriezen; Mike W P M van Beek; M Cathelijne B J E Tutein Nolthenius-Puylaert; Maurice J C van der Sangen; Rudi M Roumen; Lambertus A L M Kiemeney; Jan Willem W Coebergh
Journal:  Int J Cancer       Date:  2007-07-01       Impact factor: 7.396

3.  Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.

Authors:  Bernhard C Pestalozzi; David Zahrieh; Elizabeth Mallon; Barry A Gusterson; Karen N Price; Richard D Gelber; Stig B Holmberg; Jurij Lindtner; Raymond Snyder; Beat Thürlimann; Elizabeth Murray; Giuseppe Viale; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

4.  Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years.

Authors:  Christopher I Li; Roger E Moe; Janet R Daling
Journal:  Arch Intern Med       Date:  2003-10-13

5.  Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series.

Authors:  Giuseppe Viale; Nicole Rotmensz; Patrick Maisonneuve; Enrico Orvieto; Eugenio Maiorano; Viviana Galimberti; Alberto Luini; Marco Colleoni; Aron Goldhirsch; Alan S Coates
Journal:  Breast Cancer Res Treat       Date:  2008-07-16       Impact factor: 4.872

6.  Survival analysis between patients with invasive ductal and invasive lobular breast cancer.

Authors:  Darius Dian; Hannes Herold; Ioannis Mylonas; Christoph Scholz; Wolfgang Janni; Harald Sommer; Klaus Friese
Journal:  Arch Gynecol Obstet       Date:  2008-05-01       Impact factor: 2.344

7.  Experience with lobular carcinoma of the breast. Emphasis on recent aspects of management.

Authors:  R P Davis; P F Nora; R G Kooy; J R Hines
Journal:  Arch Surg       Date:  1979-04

8.  Infiltrating lobular carcinoma of the breast.

Authors:  J M Dixon; T J Anderson; D L Page; D Lee; S W Duffy
Journal:  Histopathology       Date:  1982-03       Impact factor: 5.087

9.  Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study.

Authors:  C Allemani; M Sant; F Berrino; T Aareleid; G Chaplain; J W Coebergh; M Colonna; P Contiero; A Danzon; M Federico; L Gafà; P Grosclaude; G Hédelin; J Macè-Lesech; C M Garcia; E Paci; N Raverdy; B Tretarre; E M I Williams
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

10.  Clinical characteristics of different histologic types of breast cancer.

Authors:  C I Li; D J Uribe; J R Daling
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

View more
  16 in total

1.  Mucinous Breast Cancer: a Review Study of 5 Year Experience from a Hospital-Based Series of Cases.

Authors:  Adrian Dumitru; Alexandru Procop; Andreea Iliesiu; Mircea Tampa; Luminita Mitrache; Mariana Costache; Maria Sajin; Anca Lazaroiu; Monica Cirstoiu
Journal:  Maedica (Buchar)       Date:  2015-03

2.  Complex Solid and Cystic Breast Cancer: A Series of Six Case Reports.

Authors:  Nishi Mehta; Lee Rousslang; Mohammad Shokouh-Amiri; Elizabeth L Wiley; Lauren Green
Journal:  J Radiol Case Rep       Date:  2020-02-29

3.  Comparison of the characteristics of medullary breast carcinoma and invasive ductal carcinoma.

Authors:  Inhye Park; Jiyoung Kim; Minkuk Kim; Soo Youn Bae; Se Kyung Lee; Won Ho Kil; Jeong Eon Lee; Seok Jin Nam
Journal:  J Breast Cancer       Date:  2013-12-31       Impact factor: 3.588

4.  The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy.

Authors:  Nava Siegelmann-Danieli; Barbara Silverman; Aviad Zick; Anat Beit-Or; Itzhak Katzir; Avi Porath
Journal:  Ecancermedicalscience       Date:  2013-12-17

5.  Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.

Authors:  Hilda Wong; Silvia Lau; Polly Cheung; Ting Ting Wong; Andrew Parker; Thomas Yau; Richard J Epstein
Journal:  BMC Cancer       Date:  2014-11-10       Impact factor: 4.430

6.  Clinicopathological Characteristics of Mucinous Breast Cancer: A Retrospective Analysis of a 10-Year Study.

Authors:  Lei Lei; Xingfei Yu; Bo Chen; Zhanhong Chen; Xiaojia Wang
Journal:  PLoS One       Date:  2016-05-27       Impact factor: 3.240

7.  Mucinous breast cancer - clinical characteristics and treatment results in patients treated at the Oncology Centre in Kraków between 1952 and 2002.

Authors:  Beata Sas-Korczyńska; Jerzy Mituś; Andrzej Stelmach; Janusz Ryś; Anna Majczyk
Journal:  Contemp Oncol (Pozn)       Date:  2014-06-03

8.  Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes.

Authors:  Monica J Engstrøm; Signe Opdahl; Lars J Vatten; Olav A Haugen; Anna M Bofin
Journal:  Histopathology       Date:  2014-12-22       Impact factor: 5.087

9.  Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population.

Authors:  SeungTaek Lim; Se Ho Park; Heong Kyu Park; Min Hee Hur; Se Jeong Oh; Young Jin Suh
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240

10.  Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database.

Authors:  Xiao-Xiao Wang; Yi-Zhou Jiang; Xi-Yu Liu; Jun-Jing Li; Chuan-Gui Song; Zhi-Ming Shao
Journal:  Oncotarget       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.